RESEARCH ARTICLE

Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis

Chun-xing Li‡, Shuo Liang‡, Lingyan Gao‡, Hua Liu*†

Department of Pharmacy, Aerospace Center Hospital, Beijing, China

‡ These authors share first authorship on this work.

* lcyx721@126.com

Abstract

Background and aims
Glucose lowering agents that reduce the risk of major adverse cardiovascular events (MACE) would be considered a major advance. The reduction of cardiovascular risk by sodium-glucose cotransporter 2 inhibitors (SGLT-2i) has been confirmed by some large-scale randomized controlled studies (RCTs) and systematic reviews of RCTs, but exact indicators of cardiovascular risk remained controversial. Whether consistent results can be obtained in clinical practice is unclear. Therefore, in this meta-analysis, we analyzed the real-world effect of SGLT-2i on cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM).

Methods
We did a real-world systematic review and meta-analysis of cardiovascular outcome of SGLT-2i in patients with T2DM. We searched PubMed and Embase for trials published up to October 23, 2019. Data search and extraction were completed with a standardized data form and any discrepancies were resolved by consensus. The primary outcome was MACE and all-cause mortality (ACM). Secondary outcomes were hospitalization for heart failure (HHF), atrial fibrillation (AF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), unstable angina (UA), heart failure (HF). Odds ratio (OR) with 95% CIs were pooled across trials, and cardiovascular outcomes were stratified by baseline incidence of cardiovascular disease (CVD), usage rate of cardiovascular benefit drug, follow-up period and region.

Results
Fourteen trials enrolling 3,157,259 patients were included. SGLT-2i reduced MACE (OR, 0.71; 95% CI 0.67,0.75, P<0.001) and ACM (OR, 0.53; 95% CI 0.49,0.57, P<0.001)
compared to other glucose lowering drugs (oGLD). Compared with oGLD, SGLT-2i had significantly lowered the risk of HHF (OR, 0.56; 95% CI 0.46, 0.68, P<0.001), MI (OR, 0.77; 95% CI 0.73, 0.81, P<0.001), stroke (OR, 0.75; 95% CI 0.72, 0.78, P<0.001), CVM (OR, 0.58; 95% CI 0.49, 0.69, P<0.001) and HF (OR, 0.56; 95% CI 0.48, 0.67, P<0.001), but there was no benefit from UA or AF. SGLT-2i significantly reduced the risk of severe hypoglycaemia (OR, 0.78; 95% CI 0.69, 0.90, P<0.001) and lower limb amputation (OR, 0.83; 95% CI 0.71, 0.98, P<0.001), but it may increase the risk of diabetic ketoacidosis. Subgroup analysis showed SGLT-2i reduced the risk of MACE, ACM, HHF, MI, stroke, CVM and HF with a similar benefit regardless of the incidence of CVD was (20–30)% or <15%, (15–30)% or <15% have been treated with GLP-1 receptor agonists (GLP-1RA), >80% or <70% have been treated with statins or both GLP-1RA and statins. SGLT-2i reduced the risk of ACM in low-risk population (P<0.001). No inconsistencies were found when stratification was performed at 1 or (3–4) years of follow-up except for BKA followed up for 1 year. SGLT-2i showed similar cardiovascular benefits in the Nordic countries, Asia and the United States.

Conclusions

The predominant impact of SGLT-2i is on cardiovascular outcome driven predominantly by reduction in MACE, ACM, HHF, MI, stroke, CVM, HF, but not UA or AF. SGLT-2i has robust benefits on reducing MACE, ACM, HHF, MI, stroke, CVM and HF regardless of a history of usage rate of GLP-1RA and/or statins and/or metformin. SGLT-2i does not increase the risk of severe hypoglycaemia and lower limb amputation.

Introduction

Diabetes mellitus is a risk factor for cardiovascular disease (CVD) and has been associated with 2- to 4-fold higher mortality [1]. CVD remains a leading cause of morbidity and mortality in patients with type 1 or type 2 diabetes mellitus (T2DM) [2]. Since 2008, US Food and Drug Administration has mandated that all new antihyperglycaemic agents must be tested for cardiovascular safety in post-marketing endpoint trials [3]. Currently, there is a paradigm shift in T2DM management, moving from a primary objective of glucose control to a cardiovascular protection. There are many glucose-lowering drugs on the market, but several of them have demonstrated significant benefits of cardiovascular protection. Metformin [4, 5] and glucagon-like peptide 1 receptor agonists (GLP-1RA) are known to have cardiovascular protective effects [6–9]. Sodium glucose cotransporter 2 inhibitors (SGLT-2i) is a relatively new drug-class of glucose-lowering medications. The risks and benefits of SGLT-2i on cardiovascular outcomes have been studied in large prospective cardiovascular outcome trials (CVOTs): CANVAS (Canagliflozin) [10], DECLARE-TIMI 58 (Dapagliflozin) [11], EMPA-REG OUTCOME (Empagliflozin) [12], which have proven their efficacy to reduce major cardiovascular events (MACE) in patients with T2DM combined with cardiovascular disease. The cardiovascular protective effect of SGLT-2i was also confirmed in several meta-analysis and systematic evaluation of randomized controlled trial (RCT) [13–15]. However, whether these positive results could be extrapolated to patients in real world clinical practice is still unknown. SGLT-2i has been reported to be related to a possible increased risk of stroke. So, we pooled evidence from real-world studies to evaluate the cardiovascular benefits of these drugs.
Materials and methods

Study retrieval and selection

Our study protocol was registered in PROSPERO (CRD: 42019119236). Published observational studies and cohort studies on the cardiovascular outcomes of SGLT-2i in patients with T2DM were identified using PubMed and Embase databases. All eligible studies in English published until October 23, 2019 were included. The search strategy was consisted of a combination of the following Mesh terms and text words: sodium-dependent glucose co-transporter 2 inhibitors, sodium-glucose co-transporter 2 inhibitors, sodium/glucose cotransporter 2 inhibitors, sodium-glucose cotransporter 2 inhibitors, SGLT2 inhibitors, Ertugliflozin, Dapagliflozin, Canagliflozin, Empagliflozin, Ipragliflozin, Tofogliflozin, Luseogliflozin, sodium-glucose transporter 2 inhibitors, BMS-512148, cardiovascular disease [MeSH Terms], cardiovascular safety, CVD, major adverse cardiovascular event, major adverse cardiac events, MACE, cardiovascular outcomes, cardiovascular effects, cardiovascular risk factors, cardiovascular benefits, cardiovascular mortality, cardiovascular events, non-fatal myocardial infarction, myocardial infarction, rehospitalization, non-fatal stroke, hospitalization for heart failure, nonfatal myocardial infarction, nonfatal stroke, cardiovascular mortality, all-cause mortality, revascularization, cardiogenic death, stroke, vascular death, non-fatal acute myocardial infarction, hospitalization for unstable angina, heart failure requiring hospitalization. Meanwhile, randomized controlled trial, randomized control trial, and RCT were excluded.

Criteria for inclusion

Studies that met the following conditions were included for this meta-analysis:

① Types of studies: prospective or retrospective observational studies, cohort studies.
② Study populations: participants were clearly diagnosed with T2DM, and participants were at least 18 years, no restrictions were applied in terms of sex or ethnicity.
③ Interventions: the experimental group administrated with SGLT-2i, the control group was treated with other glucose lowering drugs (oGLD).
④ Outcome measures: Primary outcomes: a composite cardiovascular endpoint: major adverse cardiovascular events (MACE), all-cause mortality (ACM); secondary outcomes: hospitalization for heart failure (HHF), atrial fibrillation (AF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), unstable angina (UA), heart failure (HF), severe hypoglycaemia, below the knee amputation (BKA). The list of title and abstract was assessed by 2 investigators to identify articles for full-text review. Any discrepancy or uncertainty was resolved by consensus or discussion with the other authors.

Criteria for exclusion

① Participants <18 years.
② Randomized controlled study, review articles, case reports, letters to the editor.
③ Any other non-relevant studies were excluded from analysis.

Data extraction

To avoid bias in the data abstraction process, a standardized extraction form was used, and the following data was extracted independently by 2 authors: first author, country, years of...
publication, study population, mean age of participants, number of patients, intervention plan, follow-up period, outcome measures, etc. Data extraction forms were cross-checked to verify accuracy and consistency of the extracted data. All data were checked by the third author and disagreements were resolved by discussion.

**Study quality assessment**

The quality of the studies was independently assessed by 2 authors using the Newcastle-Ottawa Scale [16]. This scale rates studies on 3 major domains: selection, comparability, and exposure. A study can be awarded a maximum of 1 point for each numbered item within the selection and exposure categories, and a maximum of 2 points can be given for comparability. The full core is 9 points (highest quality), and we assigned scores of 0–3, 4–6, and 7–9 for low, moderate, and high quality of studies, respectively.

**Statistical analysis**

The meta analysis was conducted by using Review Manager (version 5.3, The Cochrane Collaboration, Oxford, England). Stata 12.0 software (StataCorp, College Station, TX, United States) was used for publication bias analysis. Statistical heterogeneity between studies was assessed by the Cochran chi-square test complemented with the $I^2$ statistic. If chi-square test was nonsignificant ($P > 0.10$) and the $I^2$ statistic was less than 50%, it indicated a lack of heterogeneity, and fixed effect model was adopted; on the contrary, the random effect model was used for analysis. Odds ratio (OR) was used to describe the classification variables. OR was estimated by the Mantel-Haenszel $\chi^2$ method, where $P$ values $< 0.05$ were considered significantly different. Possible publication bias was assessed by Egger's and Begg's funnel plots, where $P$ values $< 0.05$ indicated little publication bias.

**Results**

**Description and quality evaluation of studies**

The literature screening process was shown in Fig 1. A total of 2209 studies were initially retrieved, and fourteen studies (3,157,259 patients) [17–30] were finally included after excluding those that did not meet the inclusion criteria. The characteristics of each study were presented in Table 1. In total, there were 1,127,629 enrolled participants in the trials who were treated with SGLT-2i, 2,029,630 were administrated with oGLD.

The quality of the studies was assessed using the Newcastle-Ottawa Scale. Studies given greater than 4 stars were recognized as being moderate to high quality. The results of this assessment were shown in S1 Table. Of the 14 studies included, 12 had a score of 8, 1 had a score of 7 and 1 had a score of 6. The quality evaluations of all included literature were of moderate and high quality.

**Primary outcomes**

**MACE.**  MACE was reported in 5 trials [17, 21, 22, 27, 30]. For the outcome of MACE, the pooled results from the fixed-effects model showed that compared with oGLD, SGLT-2i had significantly lowered the risk of MACE ($OR$, 0.71; 95% CI 0.67, 0.75; $P < 0.001$) (Fig 2). There was no heterogeneity across trials ($P = 0.55$; $I^2 = 0\%$).

**All-cause mortality.** ACM was reported in 15 trials [17–22, 24–28, 30]. For the outcome of ACM, the pooled results from the random-effects model showed that compared with oGLD, SGLT-2i had significantly lowered the risk of ACM ($OR$, 0.53; 95% CI 0.49, 0.57; $P < 0.001$) (Fig 3). There was heterogeneity across trials ($P < 0.001$; $I^2 = 62\%$).
Secondary endpoint

**CV outcomes.** The pooled results of secondary endpoint were showed in Table 2, compared with oGLD, SGLT-2i had significantly lowered the risk of HHF, MI, stroke, CVM and HF ($P < 0.001$), but there was no benefit from UA ($P = 0.51$) or AF ($P = 0.10$).

**Safety outcomes.** The pooled results of the incidence of severe hypoglycemia and BKA were showed in Table 2. Compared with oGLD, SGLT-2i had significantly lowered the risk of severe hypoglycemia ($P < 0.001$) and BKA ($P = 0.02$). The incidence rate of diabetic ketoacidosis (DKA) were 1.4 and 0.6 events per 1000 person years among SGLT-2i and DPP-4 inhibitors users, hazard ratios comparing SGLT-2i with DPP-4i was 2.14 (1.17–4.09).

Subgroup analysis

**Subgroup analysis according to the incidence of cardiovascular disease.** In the included study, the incidence of CVD in T2DM patients at baseline was (11.2–33.4)%. Toulis KA [18] and Cavender MA [25] have divided people into low-risk and high-risk subset based on their cardiovascular risk. We performed a subgroup analysis based on the incidence of CVD, and they were divided into four groups: low-risk population, high risk population, population with incidence of CVD < 15% [23, 24] and population with incidence of CVD (20–30) % [17, 20, 21, 27, 30]. Table 3 showed the results of stratified analysis. SGLT-2i significantly decreased ACM compared with oGLD in low-risk population ($P < 0.001$). SGLT-2i significantly decreased MACE, ACM, HHF, MI, stroke and CVM compared with oGLD whether the
Table 1. Summary of included studies for systematic review and meta-analysis.

| Study          | Location                                      | Design                  | Intervention               | Patients (No.) | CVD (%) | Age (y) | Female (%) | Met | GLP-1RA | Statin                  | Duration of trial (y) |
|----------------|-----------------------------------------------|-------------------------|---------------------------|----------------|---------|---------|------------|-----|---------|-------------------------|-----------------------|
| Persson F      | Denmark, Norway, Sweden                      | observational study     | dapagliflozin/DPP4i       | 10227/30681    | 23.0/22.7| 61.0±11.1/60.8±12.4 | 41.0/40.4 | 83.3/83.8 | 7.8/7.5     | 63.1/63.2              | 3.0                   |
| Tuolis KA      | United Kingdom                                | retrospective, open-cohort study | dapagliflozin/oGLD       | 4444/17680    | <23.4/27.5| 58.3±10.4/58.5±10.4 | 41.4/41.4 | -        | -           | 88.4/84.7 | 0.78±0.54/0.74±0.53 | 0.5                   |
| Cahn A         | Israel                                        | retrospective cohort study | SGLT-2i/DPP4i            | 6418/5604     | 33.4/27.5| 62.3±9.4/64.2±12.1 | 38.3/43.0 | -        | -           | -         |                       |                       |
| Kosiborod M    | South Korea, Japan, Singapore, Israel, Australia, Canada | cohort study          | SGLT-2i/oGLD            | 235064/235064 | 26.8/25.6| 56.7±12.0/56.7±12.9 | 45.0/45.5 | 73.9/74.6 | 2.6/2.6     | 65.4/65.3              | 1.02/1.07             |
| Birkeland KI   | Denmark, Norway, Sweden                       | observational study     | SGLT-2i/oGLD            | 22830/68490   | 24.9/24.8| 61.2±10.9/61.2±12.4 | 40.6/39.5 | 74.2/77.4 | 17.0/14.8   | 67.4/68.3              | 0.9±4.1               |
| Udell JA       | US                                            | population-based cohort study | SGLT-2i/ non-SGLT-2i    | 12629/12629   | -       | 65.8±8.9/65.9±9.8  | 43.3/44.9 | 78.5/83.0 | 19.5/8.1    | 82.0/81.5              | 1.6                   |
| Dawwas GK      | US                                            | retrospective cohort study | SGLT-2i/sulfonylurea     | 62767/62767   | 11.9/11.2| 54.0±12.4/54.0±9.6 | 47.7/47.6 | 57.8/58.8 | 13.9/12.5   | -                     | 1.0                   |
| Kosiborod M    | United States, Germany, Sweden, Norway, Denmark | cohort study          | SGLT-2i/oGLD            | 154528/154528 | 13.0/13.1| 56.9±10.0/57.0±10.6 | 44.3/44.5 | 78.6/79.9 | 20.3/17.5   | 67.3/67.4              | 4.0                   |
| Cavender MA    | United States, United Kingdom, Sweden, Norway, Denmark | observational study    | SGLT-2i/oGLD            | 19529/19764   | 100/100  | 62.7±9.7/63.5±10.4 | 35.9/36.6 | 75.2/79.6 | 21.8/19.6   | 81.2/82.0              | 1.02/1.07             |
| Nyström T      | Sweden                                        | observational study     | dapagliflozin/insulin    | 2047/4094     | -       | 61.2±10.4/61.1±12.8 | 38.0/37.0 | 85.0/85.0 | 16.0/16.0   | 64.0/64.0              | 1.51/1.53             |
| Pasternak B    | Denmark, Norway, Sweden                       | cohort study            | SGLT-2i/DPP4i            | 20983/20983   | -       | 61.0±10.0/61.0±10.0 | 40.0/40.0 | 79.0/79.0 | 10.0/10.0   | 67.0/67.0              | 1.1/1.7               |

(Continued)
incidence of CVD was (20–30) % or < 15% (P<0.001). ACM in the high-risk population reported only in one trial, so the pooled results could not be obtained.

**Table 1.** (Continued)

| Study                      | Location       | Design                   | Intervention                  | Patients (No.) | CVD (%) | Age (y) | Female (%) | Met (%) | GLP-1RA (%) | Statin (%) | Duration of trial (y) |
|----------------------------|----------------|--------------------------|-------------------------------|----------------|---------|---------|------------|---------|-------------|------------|----------------------|
| Patorno E 2018 [28]        | US             | Retrospective cohort study | canagliflozin/ DPP4i         | 17667/17667    | -       | 56.5 ±10.6/56.5 ±10.7 | 44.9/45.0 | 15.7/15.4 | 5.9/5.9   | 60.2/60.3 | ±0.5/0.5/0.6 |
|                           |                |                          | canagliflozin/ GLP-1RA       | 20539/20539    | -       | 56.8 ±10.9/56.7 ±10.8 | 47.3/47.2 | 16.9/16.8 | 0/0       | 61.6/61.9 | ±0.5/0.5/0.6 |
|                           |                |                          | canagliflozin/ sulfonylurea  | 17354/17354    | -       | 55.9 ±10.5/55.8 ±10.5 | 45.0/45.2 | 16.3/16.5 | 5.9/5.8   | 60.2/59.4 | ±0.5/0.5/0.6 |
| Ryan PB 2018 [29]          | US             | observational study      | canagliflozin/all non-SGLT-2i| 111332/445367  | -       | 15.0–89.0/15.0–89.0 | 42.7–64.7/42.9–65.0 | -         | -         | -         | 4.17       |
|                           |                |                          | canagliflozin/select non-SGLT-2i| 120881/319976  | -       | 15.0–89.0/15.0–89.0 | 42.7–64.7/42.9–65.0 | -         | -         | -         | 4.17       |
|                           |                |                          | empagliflozin or dapagliflozin/all non-SGLT-2i | 79626/350750 | -       | 15.0–89.0/15.0–89.0 | 42.7–64.7/42.9–65.0 | -         | -         | -         | 4.17       |
| Norhammar A 2017 [30]      | Norway, Sweden | cohort study             | dapagliflozin/ DPP4i         | 8582/25746     | 21.0/21.0 | 61.0/61.0 | 40.0/40.0 | -         | -         | -         | 0.98       |

Met.:Metformin, CVD: Cardiovascular disease, SGLT-2i: SGLT-2 inhibitor, DPP4i: DPP-4 inhibitors, GLP-1RA: glucagon-like peptide (GLP)-1 receptor agonist, oGLD: other glucose-lowering drug.

https://doi.org/10.1371/journal.pone.0244689.t001

incidence of CVD was (20–30) % or < 15% (P<0.001). ACM in the high-risk population reported only in one trial, so the pooled results could not be obtained.

**Subgroup analysis according to the usage rate of GLP-1RA, statins or metformin.** In the included studies, patients have been previously given drugs with cardiovascular benefits. (15.4–85.0) % of patients have been treated with metformin, (5.0–28.2) % with GLP-1RA and (60.2–88.4) % with statins or lipid lowering drug.

Subgroup analysis was performed according to the different utilization rates of GLP-1RA and (or) statins (S2 Table.). In the population (15–30) % [19, 21, 22, 24–26] and <15% [17, 20, 27, 28] have been treated with GLP-1RA, SGLT-2i lowered the risk of MACE, ACM, HHF,

**Fig 2. Forest plot of MACE for SGLT-2i and oGLD.**

https://doi.org/10.1371/journal.pone.0244689.g002
MI, stroke and CVM more than oGLD with significantly statistical difference ($P < 0.05$). In the population $>80\%$ [18, 22, 25] and $<70\%$ [17, 20, 21, 24–26, 28] have been treated with statins or lipid lowering drug, SGLT-2i lowered MACE, ACM, HHF, MI, stroke and CVM more than oGLD with significant statistical difference ($P < 0.001$). In the population have been treated

Fig 3. Forest plot of ACM for SGLT-2i and oGLD.

https://doi.org/10.1371/journal.pone.0244689.g003

Table 2. Results of meta-analysis on secondary endpoints.

| Outcomes  | Studies | Sample size | Heterogeneity | Model | OR     | 95% CI   | $P$    |
|-----------|---------|-------------|---------------|-------|--------|---------|-------|
| HHF       | 12      | 2510050     | $P<0.001$,$I^2=97\%$ | Random | 0.56   | 0.46,0.68 | $<0.001^*$ |
| MI        | 10      | 1039500     | $P = 0.30$,$I^2=15\%$ | Fixed  | 0.77   | 0.73,0.81 | $<0.001^*$ |
| Stroke    | 10      | 1039500     | $P = 0.23$,$I^2=23\%$ | Fixed  | 0.75   | 0.72,0.78 | $<0.001^*$ |
| CVM       | 3       | 174194      | $P = 0.26$,$I^2=26\%$ | Fixed  | 0.58   | 0.49,0.69 | $<0.001^*$ |
| UA        | 4       | 152028      | $P = 0.49$,$I^2=0\%$  | Fixed  | 0.92   | 0.73,1.17 | 0.51   |
| HF        | 5       | 606922      | $P<0.001$,$I^2=84\%$ | Random | 0.56   | 0.48,0.67 | $<0.001^*$ |
| AF        | 2       | 132228      | $P = 0.77$,$I^2=0\%$  | Fixed  | 0.92   | 0.83,1.02 | 0.10   |
| Severe hypoglycemia | 3    | 138369      | $P = 0.29$,$I^2=19\%$ | Fixed  | 0.78   | 0.69,0.90 | $<0.001^*$ |
| BKA       | 7       | 1718247     | $P<0.001$,$I^2=75\%$ | Random | 0.83   | 0.71,0.98 | 0.02   |

HHF: hospitalization for heart failure, MI: myocardial infarction, CVM: cardiovascular mortality, UA: unstable angina, HF: heart failure, AF: atrial fibrillation, BKA: below the knee amputation.

https://doi.org/10.1371/journal.pone.0244689.t002

Table 3. The results of subgroup analysis based on the risk of cardiovascular disease.

| Outcomes  | Subgroup | Studies | Sample size | Heterogeneity | Model | OR     | 95% CI   | $P$    |
|-----------|----------|---------|-------------|---------------|-------|--------|---------|-------|
| MACE      | 20–30%   | 4       | 208522      | $P = 0.69$,$I^2=0\%$  | Fixed  | 0.73   | 0.67,0.78 | $<0.001^*$ |
| ACM       | 20–30%   | 5       | 678650      | $P = 0.04$,$I^2=59\%$ | Random | 0.56   | 0.51,0.62 | $<0.001^*$ |
| Low-risk  | 2        | 280219  | $P = 0.48$,$I^2=0\%$  | Fixed  | 0.52   | 0.46,0.58 | $<0.001^*$ |
| HHF       | 20–30%   | 4       | 636684      | $P = 0.01$,$I^2=73\%$ | Random | 0.69   | 0.60,0.79 | $<0.001^*$ |
| MI        | 20–30%   | 4       | 644322      | $P = 0.57$,$I^2=0\%$  | Fixed  | 0.78   | 0.73,0.83 | $<0.001^*$ |
| <15%      | 2        | 258800  | $P = 0.25$,$I^2=25\%$ | Fixed  | 0.72   | 0.65,0.80 | $<0.001^*$ |
| Stroke    | 20–30%   | 4       | 644322      | $P = 0.67$,$I^2=0\%$  | Fixed  | 0.76   | 0.73,0.80 | $<0.001^*$ |
| <15%      | 2        | 258800  | $P = 0.62$,$I^2=0\%$  | Fixed  | 0.68   | 0.62,0.75 | $<0.001^*$ |
| CVM       | 20–30%   | 3       | 174194      | $P = 0.26$,$I^2=26\%$ | Fixed  | 0.58   | 0.49,0.69 | $<0.001^*$ |

MACE: major adverse cardiovascular events, ACM: all-cause mortality, HHF: hospitalization for heart failure, MI: myocardial infarction, CVM: cardiovascular mortality.

https://doi.org/10.1371/journal.pone.0244689.t003

MI, stroke and CVM more than oGLD with significantly statistical difference ($P < 0.05$). In the population $>80\%$ [18, 22, 25] and $<70\%$ [17, 20, 21, 24–26, 28] have been treated with statins or lipid lowering drug, SGLT-2i lowered MACE, ACM, HHF, MI, stroke and CVM more than oGLD with significant statistical difference ($P < 0.001$). In the population have been treated
with statins (<70%) and GLP-1RA (<15%) at low rates [17, 20, 27, 28], SGLT-2i lowered the risk of MACE, ACM, HHF, MI, stroke and CVM with significant statistical difference ($P<0.05$). In the population have been treated with statins (>80%), GLP-1RA (15–30) % and metformin (>75%) at high rates [22, 25], SGLT-2i lowered ACM more than oGLD with significant statistical difference ($P<0.001$). There was no significant difference in UA between the two groups in the population have treated with GLP-1RA (<15%) and/or statins (<70%) ($P = 0.51$).

**Subgroup analysis according to different regions.** Subgroup analysis was performed according to studies in different regions, including the Nordic countries (Denmark, Norway, and Sweden) [17, 21, 25–27], Asia (Korea, Japan) [19, 20] and the United States [6, 7, 12, 13].

**HHF in Asia.** HHF in Asia was reported in 2 trials. The pooled results from the fixed-effects model showed that compared with oGLD, SGLT-2i had significantly lowered the risk of HHF (OR, 0.80; 95% CI 0.76,0.85; $P <0.001$) (S3 Table).

**In Nordic countries.** MACE, ACM, HHF, MI and stroke in the Nordic countries were reported respectively in 4, 5, 3 and 3 trials. The pooled results showed that compared with oGLD, SGLT-2i had significantly lowered the risk of MACE, ACM, HHF, MI and stroke ($P < 0.05$) (S3 Table).

**In the United States.** ACM, HHF, MI and stroke in the United States were reported respectively in 4, 7, 6 and 6 trials. The pooled results showed that compared with oGLD, SGLT-2i had significantly lowered the risk of ACM, HHF, MI and stroke ($P < 0.05$) (S3 Table).

**Subgroup analysis according to follow-up period.** The subgroup was further analyzed according to the length of follow-up. The included studies were followed up for up to (3–4) years [17, 24, 29], 1 year [18, 20–23, 25–27, 30], and 6 months [19, 28]. Since the data of 6 months was only from two studies, we pooled the date of (3–4) years and 1 year. The results of subgroup analysis were consistent with the whole group analysis. SGLT-2i significantly reduced the risk of MACE, ACM, HHF, MI, stroke, CVM and HF than oGLD ($P<0.05$). There was no statistically significant difference in the risk of BKA in the SGLT-2i group after one-year follow-up (S4 Table).

**Sensitivity analyses**

We deleted one single study from the overall pooled analysis each time to check the influence of the removed data set on the overall OR. If there is significant change, the results are considered unstable; otherwise, they are considered stable. The analysis results of all outcomes showed no significant change, so the research results were stable.

**Publication bias**

All outcomes were examined by Egger’s and Begg’s, and the results (S5 Table) showed that publication bias might exist in MI ($P = 0.049$), while it did not exist in any other outcomes ($P>0.05$).

**Discussion**

In this real-world meta-analysis of 14 trials enrolling 3,157,259 participants with T2DM, approximately (11.2–33.4) % of the study population had a previous CVD event (ischemic heart disease, stroke, and/or heart failure). The treatment regimen of the experimental group was SGLT-2i, including Dapagliflozin [17–27, 29], Ipraglifozin [19, 20], Canagliflozin [20–23, 25, 27–29], Empagliflozin [20–23, 25, 27, 29], Tofogliflozin [20], Luseogliflozin [20]. The control group was treated with oGLD, including DPP-4 inhibitors, metformin, sulfonylureas, GLP-1RA, thiazolidinediones, insulin. Both groups were combined with drugs that can
provide cardiovascular benefits included angiotensin converting enzyme inhibitors, statins and antiplatelet. We found that compared with oGLD, SGLT-2i had been associated with significant risk reduction of MACE, ACM, HHF, MI, stroke, CVM and HF. However, we did not find that SGLT-2i resulted in a lower risk of UA and AF.

CANVAS trial showed patients treated with Canagliflozin had significantly lower risk of MACE, HHF than patients assigned to placebo, but ACM, CVM, MI, stroke were not considered to be significant [10]. DECLARE-TIMI 58 trial showed Dapagliflozin did not result in a lower rate of MACE, ACM, MI, CVM and stroke, but did result in a lower rate of HHF [11]. EMPA-REG OUTCOME trial showed Empagliflozin reduced the risk of MACE, ACM, HHF, CVM, while, there were no significant between-group differences in the occurrence of MI or stroke [12]. Participants in CANVAS trial, DECLARE-TIMI 58 trial and EMPA-REG OUTCOME trial were diabetic patients with established cardiovascular disease or at high risk for cardiovascular disease. In our pooled analysis, only about (10–30) % of patients were diagnosed with CVD, with a lower cardiovascular prevalence than in those three randomized controlled trials (RCTs). But our meta-analysis from the real world showed that SGLT-2i was associated with greater cardiovascular benefit than the three RCTs that have been published. Strict inclusion and exclusion criteria and rigorous safety monitoring may limit the generalizability of RCT results.

Our results were consistent with the results of the meta-analysis from the RCT of Usman MS, et al. The difference was that Usman MS's study showed no significant difference in stroke [31]. Zelniker TA, et al found SGLT-2i reduced the risk of MACE by 11% with benefit only seen in patients with atherosclerotic cardiovascular disease and not in those without [15]. We found different results from subgroup analyses based on the prevalence of CVD. SGLT-2i significantly decreased the risk of MACE, ACM, HHF, MI, stroke and CVM compared with oGLD whether the incidence of CVD was (20–30) % or < 15%. SGLT-2i significantly decreased ACM compared with oGLD in low-risk population, which only came from a pooled analysis of two studies. Cohort studies showed Canagliflozin had no treatment heterogeneity between patients with and without established heart failure or CVD [28]. Unfortunately, we could not do more than ACM in low risk populations. Therefore, more studies are needed to verify the cardiovascular benefits of SGLT-2i in people with low risk of CVD.

The usage rate of cardiovascular benefit drugs such as GLP-1RA, Metformin, statins in the included studies varied. When stratified according to the usage rate of drugs for cardiovascular benefit at baseline, we got consistent results regardless of high or low usage rate. SGLT-2i lowered MACE, ACM, HHF, MI, stroke and CVM more than oGLD with significantly statistical difference. Although the studies included were real-world cohort studies, they were generally balanced by propensity score matching before data analysis. There was no significant difference in the use of other drugs between SGLT-2i group and oGLD group, which suggested that the cardiovascular benefits were mainly due to the use of SGLT-2i.

The participants included came from different regions such as the Nordic countries, the United States, Asia and the Middle East. Different regions have different insurance types or no insurance coverage, as commercially insured patients are more likely to have differential socioeconomic status, drug adherence, and risk factors for cardiovascular disease. We performed stratified analysis on the population from different regions. No matter in the Nordic countries or the United States, SGLT-2i can significantly reduced the risk of ACM, HHF, MI and stroke. Unfortunately, studies of participants from Asia only had two studies, pooled analysis of two Asia studies showed SGLT-2i can significantly reduce the risk of HHF in Asia.

The follow-up time of the included study was (0.6–4.0) years. Insufficient follow-up time may affect the results of the study. Subgroup analysis showed SGLT-2i significantly reduced MACE, ACM, HHF, MI, stroke, CVM and HF than oGLD whether they were followed up for
(3–4) years or 1 year. SGLT-2i failed to significantly reduce ACM in the pooled two studies with a follow-up of 6 months, which depended largely on Patorno E’s study [28]. Interventions in one of the cohort was SGLT-2i vs. GLP-1RA of Patorno E’s study [28]. A network meta-analysis showed the use of SGLT-2i or GLP-1RA was associated with similar lower mortality than DPP-4 inhibitors or placebo or no treatment [32]. On the other hand, the short duration of follow-up explained the lower observed death rates compared with the long duration trials.

In terms of safety, our study showed that SGLT-2i reduces the risk of severe hypoglycemia and lower limb amputation. Burt, there was no statistically significant difference in the risk of lower limb amputation in the SGLT-2i group after one-year follow-up. Currently, studies on the risk of lower limb amputation are controversial. Several observational studies have shown that SGLT-2i does not increase the risk of lower limb amputation [33–35]. But other observational studies have shown contrary results [36, 37]. Several meta analyses from RCT all showed that SGLT-2i were not significantly associated with risk of amputation [38, 39]. Subgroup analysis showed an increased incidence of amputation in participants using Canagliflozin [38]. Another meta analysis showed that neither Canagliflozin nor SGLT-2i increase the risk of amputation [40].

Only one of the included studies mentioned that SGLT-2i increased the risk of DKA. Register based cohort study showed SGLT-2i was associated with an increased risk of DKA (HR: 2.14, 1.01–4.52) compared with GLP-1RA [36]. A multicenter cohort study found SGLT-2i was associated with an increased risk for DKA (HR:2.85, 1.99–4.08) compared with DPP-4 inhibitors [41]. A meta-analysis of random controlled trials showed that SGLT-2i did not increase the risk of DKA (MH-OR:1.14, 0.45–2.88; P = 0.78) [42]. In summary, real world study data showed that SGLT-2i increases the risk of DKA differently than RCT data.

Our study included a large sample size and performed a subgroup analysis. However, our study also had several limitations as following: Firstly, We used aggregated study-level data rather than individual participant data. Secondly, fewer included studies performed subgroup analysis on the high-risk and low-risk groups of CVD. Therefore, besides SGLT-2i could reduce the risk of ACM, we could not find out more about the cardiovascular benefits of SGLT-2i in the low-risk population. Thirdly, although stratified analyses were performed based on the prevalence of CVD and the use of drugs for cardiovascular benefits in the included studies, approximately 40% of the included studies were not included in the subgroup analysis because no detailed cardiovascular prevalence or use of drugs for cardiovascular benefits were reported. Fourthly, participants in the study were mainly from Nordic countries and the United States, only a small quantity of them were from Asia. Therefore, we need cardiovascular outcomes of SGLT-2i for participants in East Asia especially China. Fifthly, there were few studies on severe adverse reactions, so whether SGLT-2i increases the risk of BKA and DKA cannot be fully assessed. Sixthly, unfortunately, we were unable to conduct a pooled analysis of the effects of SGLT-2i on blood pressure due to the lack of relevant data in the included studies. Finally, some heterogeneity appears to exist between different brands of SGLT-2i, due to the limited data we cannot fully explore through subgroup.

**Conclusion**

In summary, our study showed that among patients with T2DM who had an increased risk of CVD, SGLT-2i significantly reduced the risk for MACE, ACM, HHF, MI, stroke, CVM and HF regardless of the incidence of CVD was (20–30) % or <15%, (15–30) % or <15% have been treated with GLP-1RA, >80% or <70% have been treated with statins or both GLP-1RA and statins. No inconsistencies were found when stratification was performed at 1 and (3–4) years of follow-up. SGLT-2i showed similar cardiovascular benefits in Nordic countries, Asia.
and the United States. In terms of severe adverse reactions, our study showed that SGLT-2i did not increase the risk of severe hypoglycemia and lower limb amputation, but whether SGLT-2i increases the risk of lower limb amputation still needs further evaluation. Observational studies have generally shown that SGLT-2i increased the risk of diabetic ketosis. Therefore, clinician should pay attention to monitoring adverse reactions in diabetes treatments.

Supporting information
S1 Table. Quality assessment of included studies according to the Newcastle-Ottawa Scale. (DOCX)
S2 Table. The results of subgroup analysis based on the usage rate of GLP-1RA and/or statins. (DOCX)
S3 Table. Cardiovascular outcomes of subgroup analysis according to different regions. (DOCX)
S4 Table. Cardiovascular outcomes of subgroup analysis according to follow-up period. (DOCX)
S5 Table. The publication bias of Begg’s test and Egger’s test. (DOCX)
S1 Checklist. PRISMA 2009 checklist. (DOC)
S1 Data. (XLSX)

Acknowledgments
The authors would like to thank Xiangshan Tan and Chunlin Chen for reviewing our manuscript.

Author Contributions
Conceptualization: Chun-xing Li.
Data curation: Chun-xing Li.
Formal analysis: Chun-xing Li.
Methodology: Chun-xing Li, Shuo Liang, Lingyan Gao.
Software: Chun-xing Li.
Validation: Chun-xing Li, Hua Liu.
Writing – original draft: Chun-xing Li.
Writing – review & editing: Chun-xing Li, Shuo Liang, Lingyan Gao, Hua Liu.

References
1. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019; 8(4): e11295.
2. Schmidt AM. Diabetes mellitus and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019; 39(4): 558–568. https://doi.org/10.1161/ATVBAHA.119.310961 PMID: 30786741
3. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. JAMA. 2019; 321(17): 1720–1721. https://doi.org/10.1001/jama.2019.2702 PMID: 31063571

4. Han Y, Xie H, Liu Y, Gao P, Yang XF, Shen ZJ. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019; 18(1): 96. https://doi.org/10.1186/s12933-019-0900-7 PMID: 31362743

5. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017; 60(9): 1620–1629. https://doi.org/10.1007/s00125-017-4337-9 PMID: 28770324

6. Marso SP, Daniels GH, Brown- Forbes K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–322. https://doi.org/10.1056/NEJMoa1603827 PMID: 27295427

7. Scheen AJ. Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol. 2017; 5(4): 236–238. https://doi.org/10.1016/S2213-8587(17)30012-8 PMID: 28110912

8. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–1844. https://doi.org/10.1056/NEJMoa1601411 PMID: 27633186

9. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228–1239. https://doi.org/10.1056/NEJMoa1612917 PMID: 28910237

10. Neal B, Perkovic V, Mahaffey KW, Zeeuwa D, Fulcher G, Endo N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–657. https://doi.org/10.1056/NEJMoa1812389 PMID: 30415602

11. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–357. https://doi.org/10.1056/NEJMoa1907588 PMID: 30850608

12. Zinman B, Wiviott SD, Raz I, Bonaca MP, Kato ET, Cahn A, et al. Dapagliflozin in type 2 diabetes: a randomized trial. N Engl J Med. 2019; 381(24): 2295–2306. https://doi.org/10.1056/NEJMoa1900747 PMID: 31001774

13. Radholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW, et al. Effects of sodium-glucose co-transporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—a systematic review. Diabetes Res Clin Pract. 2018; 140: 118–128. https://doi.org/10.1016/j.diabres.2018.03.027 PMID: 29604389

14. Sinha B, Ghosal S. Sodium-glucose co-transporter-2 inhibitors (SGLT-2) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events: a meta-analysis. Diabetes Ther. 2019; 10(3): 891–899. https://doi.org/10.1007/s13300-019-00597-3 PMID: 30875065

15. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39. https://doi.org/10.1016/S0140-6736(18)32590-X PMID: 30424892

16. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analysis. 2019; 2: 1. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

17. Persson F, Nyström T, Jorgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018; 20(2): 344–351. https://doi.org/10.1111/dob.13077 PMID: 28771923

18. Toulis KA, Willis BH, Marshall T, Kumarendran B, Gokhale K, Ghosh S, et al. All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the health improvement network database[J]. J Clin Endocrinol Metab. 2017; 102(5): 1719–1725. https://doi.org/10.1210/jc.2016-3446 PMID: 28323967

19. Cahn A, Melzer-Cohen C, Pollack R, Kumarendran B, Gokhale K, Ghosh S, et al. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab. 2019; 21(2): 340–348. https://doi.org/10.1111/dob.13532 PMID: 30207040

20. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 Study. J Am Coll Cardiol. 2018; 71(23): 2628–2639. https://doi.org/10.1016/j.jacc.2018.03.009 PMID: 29540325

21. Birkeland KI, Jorgensen ME, Carstensen B, Persson F, Gulseth H, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational
Cardiovascular outcomes associated with SGLT-2i in patients with type 2 diabetes: A real-world meta-analysis

Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter (SGLT-2i) and lower extremity amputation among patients with type 2 diabetes[J]. JAMA Intern Med. 2018; 178(9): 1190–1198. https://doi.org/10.1001/jamainternalmed.2018.3024 PMID: 30039524

22. Udei JA, Yuan Z, Rush T, Sicignano NM, Gaitlz M, Rosenthal N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study [evidence for cardiovascular outcomes with sodium-glucose cotransporter 2 inhibitors in the real world][J]. Circulation. 2018; 137(14): 1450–1459. https://doi.org/10.1161/CIRCULATIONAHA.117.031227 PMID: 2913607

23. Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes[J]. Diabetes Obes Metab. 2019; 21(1): 28–36. https://doi.org/10.1111/dom.13477 PMID: 30039524

24. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose-cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose-cotransporter-2 inhibitors)[J]. Circulation. 2017; 136(3): 249–259. https://doi.org/10.1161/CIRCULATIONAHA.117.029190 PMID: 28522450

25. Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL[J]. J Am Coll Cardiol. 2018; 71(22): 2497–2506. https://doi.org/10.1016/j.jacc.2018.01.085 PMID: 29852973

26. Nystrom T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes[J]. Diabetes Obes Metab. 2017; 19(6): 831–841. https://doi.org/10.1111/diabet.12889 PMID: 28116795

27. Pastemak B, Ueda P, Eliasson B, Svensson A, Franzén S, Gudbjörnsdottir S, et al. Use of sodium-glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure; Scandinavian register based cohort study[J]. BMJ. 2019; 366: i4772. https://doi.org/10.1136/bmj.i4772 PMID: 31467044

28. Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study[J]. BMJ. 2018; 360: k119. https://doi.org/10.1136/bmj.k119 PMID: 29437648

29. Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D)[J]. Diabetes Obes Metab. 2018; 20(11): 2585–2597. https://doi.org/10.1111/diabet.13424 PMID: 29938883

30. Norhammar A, Bodegard J, Nystrom T, Nathanson D, Gulseth HL, Thuresson M, et al. Dapagliflozin is Associated with lower risk of hospitalization for heart failure, major adverse cardiovascular events and all cause death compared to DPP-4i in T2D patients: CVD-REAL Nordic[J]. Can J Diabetes. 2017; 41(5): S22–S33.

31. Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Ayub MT, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis[J]. Eur J Prev Cardiol. 2018; 25(5): 495–502. https://doi.org/10.1177/2047487318755531 PMID: 29372664

32. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shiin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis[J]. JAMA. 2018; 319(6): 1580–1591. https://doi.org/10.1001/jama.2018.3024 PMID: 29677303

33. Chang HY, Singh S, Mansour O, Baksh S, Alexander GC. Association between sodium-glucose cotransporter 2 Inhibitors and lower extremity amputation among patients with type 2 diabetes[J]. JAMA Intern Med. 2018; 178(9): 1190–1198. https://doi.org/10.1001/jamainternalmed.2018.3034 PMID: 30105337

34. Adimadhayam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study [J]. Diabetes Obes Metab. 2018; 20(12): 2792–2799. https://doi.org/10.1111/diabet.13459 PMID: 29971914

35. Sung J, Padmanabhan S, Gurung S, Inglis S, Vicaretti M, Begg L, et al. SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic[J]. J Clin Transl Endocrinol. 2018; 13: 46–47. https://doi.org/10.1016/j.jcte.2018.07.002 PMID: 30094190

36. Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson A, Franzén S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study[J]. BMJ. 2018; 363: k4365. https://doi.org/10.1136/bmj.k4365 PMID: 30429124
37. Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, et al. Sodium-glucose cotransporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers[J]. Diabetes Obes Metab. 2019; 21(5): 1223–1236. https://doi.org/10.1111/dom.13647 PMID: 30697897

38. Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis[J]. PLoS One. 2020; 15(6): e0234065. https://doi.org/10.1371/journal.pone.0234065 PMID: 32502190

39. Dicembrini I, Tomberli B, Nreu B, Baldereschi GI, Fanelli F, Mannucci E, et al. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials[J]. Diabetes Res Clin Pract. 2019; 153: 138–144. https://doi.org/10.1016/j.diabres.2019.05.028 PMID: 31150722

40. Miyashita S, Kuno T, Takagi H, Sugiyama T, Ando T, Valentin N, et al. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials[J]. Diabetes Res Clin Pract. 2020; 163: 108136. https://doi.org/10.1016/j.diabres.2020.108136 PMID: 32272190

41. Douros A, Lix LM, Fralick M, Dell’Aniello S, Shah BR, Ronksley PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A Multicenter Cohort Study[J]. Ann Intern Med. 2020; 173(6): 417–425. https://doi.org/10.7326/M20-0289 PMID: 32716707

42. Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials[J]. Diabetes Res Clin Pract. 2017; 130: 53–60. https://doi.org/10.1016/j.diabres.2017.04.017 PMID: 28570924